The prediction was lowered in the midst of a decline in US financing for biotech. In an exchange statement on October 17, the business stated, “We now expect the revenue to grow at mid-teens on a constant currency basis.”
The firm announced a 14.22% rise in consolidated net profit for the quarter that ended in September, coming in at Rs 116.5 crore as opposed to Rs 102 crore the previous year.
For the current fiscal quarter, Syngene’s operating revenue was Rs 910.1 crore, up from Rs 768.1 crore during the same period last year. Furthermore, compared to the same time last year, the company’s overall costs jumped to Rs 773.6 crore from Rs 653.5 crore.
Jonathan Hunt, the managing director and CEO of Syngene International, stated that the business has achieved impressive achievements in the second quarter and first half of the current fiscal year, especially in its research and production services. “In development services, we also added a new non-GMP capability centre to meet market demand for agile, cost-efficient, early phase development and scale-up services,” he stated.
Notice: Moneycontrol.com experts’ opinions and financial advice are their own, not the website’s or its management’s. Users are advised by Moneycontrol.com to consult with qualified professionals prior to making any financial decisions.